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Abstract
Background—Many patients with major depressive disorder (MDD) who begin antidepressant 
treatment discontinue use before for six months, the recommended minimum treatment length. 
This study sought to identify predictors of six-month antidepressant persistence including 
predictors utilizing patients’ electronic prescription records.
Methods—Commercially insured children (3–17 years) and adults (18–64 years) with MDD who 
initiated antidepressant treatment, 1/1/2003–2/28/2010, were assessed for six-month persistence 
(based on prescriptions’ days supply, allowing a 30-day grace period). Antidepressant persistence 
prediction models were developed separately for children and adults. Two additional measures, 
days without medication between the first and second antidepressant fill (children and adults) and 
prior persistence on other medications (adults only), were added to the models, concordance (c) 
statistics were compared and risk reclassification evaluated.
Results—Among children (n=8,837 children) and adults (n=47,495) with MDD, six-month 
antidepressant persistence was low and varied by age (37%, 18–24 years to 52%, 3–12 and 50–64 
years, respectively). Independent baseline predictors of persistence were identified, with model c-
statistics: children=0.582, adults=0.584. Patients with more days without medication between fills 
were less likely to be persistent (10–30 vs. 0 days, children: RR=0.72, adults: RR=0.74), as were 
adults not previously persistent to other medications (RR=0.73).
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Limitations—The definition of 6-month persistence is dependent on correct days supply values 
and the grace period utilized; potential predictors were limited to measures available in claims 
data.
Conclusions—Six-month antidepressant persistence was low and overall prediction of 
persistence was poor; however, days without medication between fills and prior persistence on 
other medications marginally improved the ability to predict antidepressant persistence.
INTRODUCTION
The American Psychiatric Association (APA) recommends that patients with mild to severe 
major depressive disorder (MDD) treated with antidepressants receive a minimum of 6–12 
weeks of treatment to achieve symptom remission followed by 4–9 months of treatment to 
prevent relapse (American Psychiatric Association, 2010). Organizations outside the United 
States (US) also recommend that patients with MDD continue antidepressant treatment for 
≥6 months following symptom remission (Kennedy SH et al., 2009; National Collaborating 
Centre for Mental Health, 2005; National Institute for Health and Care Excellence, 2009; 
Nutt DJ et al., 2010). Nevertheless, low rates of 6-month antidepressant persistence have 
been observed in children and adults (Esposito D et al., 2009; Fontanella CA et al., 2011; 
Hansen D et al., 2004; Lu C and Roughead E, 2012; Mullins CD et al., 2005; Sawada N et 
al., 2009; Tournier M et al., 2009; Wu C et al., 2013; Yau WY et al., 2014).
Persistence, defined as the length of time between medication initiation and medication 
discontinuation, is a component of adherence, which is defined as the process by which 
patients take medication as prescribed (Vrijens B et al., 2012). Most previous studies 
examining factors related to persistence focused on adults. Factors identified in these studies 
include gender, age, race, education, co-morbidities, concomitant medication use, 
medication cost, adverse side effects, antidepressant agent, insurance type, follow-up visits, 
and symptom improvement (Assayag J et al., 2013; Bull SA et al., 2002; Esposito D et al., 
2009; Hansen D et al., 2004; Lu C and Roughead E, 2012; Mullins CD et al., 2005; Sawada 
N et al., 2009; Wu C et al., 2012; Wu C et al., 2013; Yau WY et al., 2014). Beyond baseline 
measures, gaps in antidepressant prescription refills based on administrative pharmacy 
records predicted antidepressant discontinuation in adults. Specifically, a 14-day gap in 
medication supply during the first 90 days of treatment identified four of every five patients 
at risk for discontinuing (Hansen RA et al., 2010). Additionally, in other settings, adherence 
(measured by the medication possession ratio) to medications taken for unrelated chronic 
indications improved the prediction of oral bisphosphonate adherence (Curtis JR et al., 
2009). Adherence to antidepressant treatment (90 days of medication supply in first 180 
days after initiation) was a marginal predictor of concurrent antihypertensive and lipid-
lowering medication adherence (medication possession ratio ≥80%) (Simon GE et al., 2013). 
It was unknown whether prior persistence on other chronic medications, a measure available 
prior to antidepressant initiation, and antidepressant refill gaps, a measure available soon 
after antidepressant initiation, would improve the ability to predict antidepressant 
persistence. As these measures could be made readily available to clinicians through 
prescription refill records (or by patient self-report), estimating whether they offer an 
advantage over standard predictors could potentially prove useful.
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In Medicaid-enrolled children, factors previously identified as associated with higher 
antidepressant adherence (measured by the proportion of days with medication) during the 
treatment continuation phase include use of other psychotropic drugs, absence of substance 
use disorders, and foster-case Medicaid eligibility (Fontanella CA et al., 2011). By contrast, 
factors associated with antidepressant persistence in children have not been identified. 
Whether important variation in predictors of persistence in children and adults differ is 
unknown. To expand upon the existing literature the current study a) estimates 6-month 
antidepressant persistence for children and adults with MDD in a large US commercially 
insured population, b) creates and validates a baseline prediction model for antidepressant 
persistence separately in children and adults, and c) determines if our baseline prediction 
model improves when a patient’s delay in filling the second antidepressant prescription and 
a patient’s prior persistence on other chronic medications are taken into account.
METHODS
Data source & study population
Data for this analysis was drawn from the LifeLink Health Plan Claims Database, purchased 
from IMS Health (IMS Health Incorporated, 2015). The database covers commercially 
insured individuals and their dependents across the US, containing medical and 
pharmaceutical claims for approximately 60 million unique patients from 98+ US health 
plans. The database includes inpatient and outpatient International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, Current 
Procedural Terminology, 4th edition, and Healthcare Common Procedure Coding System 
procedure codes and records for reimbursed, dispensed prescriptions. The database has been 
used in the past for epidemiologic research involving antidepressants (Miller M et al., 
2014b; Valuck RJ et al., 2007) including studies describing adults and children initiating 
antidepressant therapy (Czaja AS and Valuck R, 2012; Milea D et al., 2010). The University 
of North Carolina Institutional Review Board deemed the study exempt from review.
The study cohort includes children (3–17 years) and adults (18–64 years) with a diagnosis of 
MDD who initiate an SSRI or SNRI between January 2003 and February 2010. MDD was 
defined as an inpatient or outpatient diagnosis (ICD-9-CM: 296.2x, 296.3x) in the year prior 
to antidepressant initiation. SSRIs (sertraline, citalopram, escitalopram, fluoxetine, 
paroxetine) and SNRIs (venlafaxine, duloxetine) included in the study were limited to those 
FDA approved for depression and those more commonly used. Patients were required to 
have no record of any antidepressant use in the prior year, to have continuous insurance 
enrollment in the prior year and in the 6 months following antidepressant initiation, and, to 
avoid imputation, a days supply value >0 for the index antidepressant prescription and 
prescriptions in the following 6 months. Patients with a diagnosis of bipolar disorder in the 
prior year were excluded.
Antidepressant persistence
To calculate persistence, defined as ≥6 months between antidepressant initiation and 
antidepressant discontinuation, we followed each patient beginning on the index 
antidepressant’s dispensing date. For each prescription dispensing date, the days supply of 
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medication was added to a 30-day grace period, to account for missed doses. If there was no 
refill by the end of the days supply plus grace period, the patient was considered to have 
stopped treatment at that point. The patient was categorized as non-persistent if treatment 
had been stopped before 180 days after the index antidepressant’s dispensing date; otherwise 
the patient was categorized as persistent. A 30-day grace period was selected because the 
majority (89%) of patients had an initial days supply value for ≤30 days (only 5% had an 
initial days supply of ≥90 days). Additionally, a longer grace period would have 
overestimated 6-month persistence. For a sensitivity analysis we used a more restrictive 15-
day grace period. Switching SSRI, SNRI, or between SSRI and SNRI agents was regarded 
as treatment continuation.
Potential predictors
Potential predictors of persistence were collected in the year prior to antidepressant initiation 
and included age, sex, psychiatric and non-psychiatric co-morbidities, healthcare utilization, 
antidepressant class (SSRI, SNRI), prior suicide attempt (external cause of injury codes: 
E950.x–E959.x), high and mid-potency prescription opiate usage, recurrent MDD diagnosis 
(ICD-9-CM: 296.3x), and service provider type for the index antidepressant. Patient 
copayment for the index antidepressant was calculated by subtracting the amount paid by the 
insurance plan from the amount the insurance plan allowed per prescription (typically the 
amount paid plus patient liability). Copayment was categorized as low vs. high based on the 
copayment value at the 75th percentile for children (low: <$16) and adults (low: <$24). 
Initial antidepressant dose was categorized into low, non-low, and unknown. Low initial dose 
was defined per agent based on available guidelines for starting dose (American Psychiatric 
Association, 2010; British Columbia Ministry of Health, 2013; Geller DA et al., 2012; 
National Collaborating Centre for Mental Health (UK), 2005; Nutt DJ et al., 2010). The 
measures for substance use included patients with a substance use related hospitalization and 
patients with a substance use disorder diagnosis without a hospitalization. We constructed a 
hierarchical measure of depression severity with depression-related diagnoses characterized 
as inpatient vs. outpatient diagnosis and timing of the inpatient diagnosis, i.e. within 30 days 
of antidepressant initiation vs. 31–360 days (Miller M et al., 2014a).
Days without medication & prior persistence on other medications
We created a measure of days without medication between the first and second 
antidepressant prescription fill and a measure of prior persistence on other chronic 
medications. The measure of days without medication was calculated by subtracting the 
index days supply from the number of days between the dispensing dates of the first and 
second prescriptions (categorized to 0, 1–9, or 10–30 days). The measure was estimated only 
in the subset of patients who filled a second antidepressant prescription before the end of the 
first 30-day grace period. The measure of prior persistence on other medications was based 
on use of anti-hyperlipidemics, anti-hypertensives, bone-density regulators, or chronic 
asthma medications, medications customarily taken consistently. As these and other 
medications for chronic conditions are not commonly prescribed for children, prior 
persistence on other medications was assessed only in adults. We defined prior persistence 
on other medications as the use of that medication for at least 180 days before antidepressant 
initiation. Therefore, the measure of prior persistence on other medications was created only 
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in adults with a record of a dispensed prescription for a chronic medication in the 6–12 
months prior to antidepressant initiation. All other adults were excluded from the analyses 
involving the measure of prior persistence on other medications. Patients with 180 days of 
continued use on ≥1 unrelated chronic medication in the year before antidepressant 
initiation, allowing a 30-day grace period, were considered persistent to prior other chronic 
medications. Figure 1 summarizes the study design.
Statistical analyses
We estimated the proportion of patients persistent on antidepressant treatment at 6 months 
overall and for each predictor, with 95% confidence intervals (CI) by age group. We used 
log-binomial regression to determine the adjusted risk ratios (RR) with 95% CIs for 6-month 
persistence. Predictors with a p-value <0.05 and a magnitude of effect ≥5% in the RR of 
persistence (in at least 1 strata for categorical variables), were included in the baseline 
prediction model. To provide a measure of model fit, the concordance (c) statistic was 
calculated. The c-statistic is a rank-based measure of discrimination representing the 
probability a randomly selected pair of persistent and non-persistent subjects will be 
correctly ranked with regards to their antidepressant persistence status, ranging from 0.5 (no 
discrimination) to 1.0 (perfect discrimination) (Cook NR, 2007; Hanley JA and McNeil BJ, 
1982). When calculating the c-statistic, we entered age, copayment, outpatient visit count, 
and generic prescription drug count as continuous variables with polynomial terms added 
based on a likelihood ratio test (p<0.1). After adding the measure of days without 
medication between fills (continuous with polynomial term) and prior persistence on other 
medications to the baseline prediction models we recalculated the c-statistics. In the subset 
of adults with both a measure of prior persistence on other medications and a measure of 
days without medication we used a classification and regression tree (CART) to determine if 
interactions were present between predictors of antidepressant persistence, particularly 
between days without medication and prior persistence on other medications. We set the 
minimum number of observations per node to attempt a split to 30 and the complexity 
parameter (cp) to 0.002; we used tree pruning to balance complexity with model fit (final 
cp=0.0032) (Lewis RJ, 2000; Therneau T et al., 2015).
To better evaluate the clinical utility of the measure of days without medication and the 
measure of prior persistence on other medications we assessed clinical risk classification. 
Risk reclassification cross-classifies patients into strata of predicted probabilities of 
antidepressant persistence based on the baseline prediction model with and without an 
additional measure (Cook NR, 2008; Cook NR et al., 2006). Improved reclassification 
occurred when persistent patients moved into a higher strata of predicted probability after 
the additional measure was added and when non-persistent patients moved into a lower 
strata (Ridker PM et al., 2008). Reclassification tables are stratified by observed 
antidepressant persistence status (Pencina MJ et al., 2008). In the absence of predefined risk 
categories for antidepressant persistence, we selected a 15% window around the observed 
mean 6-month antidepressant persistence in each subset. These three categories created 
clinically meaningful groupings that separated patients with a low likelihood of 
antidepressant persistence from those with a higher likelihood. A wider window was not 
used given the narrow distribution of predicted probabilities of antidepressant persistence 
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from the baseline prediction models (ex. interquartile range in the adult baseline model=40–
50%). We calculated the overall net reclassification improvement (NRI) to summarize the 
improvement in the distribution of patients across the strata when each additional measure 
was added (positive NRI=improved reclassification, with more benefit seen as the NRI 
increases) (Leening MJG et al., 2014; Pencina MJ et al., 2008). Analyses were conducted in 
SAS version 9.3 (Cary, NC) and R version 3.2.0.
RESULTS
Between January 2003 and February 2010, 770,246 patients aged 3–64 years initiated an 
SSRI or SNRI with no antidepressant use in the prior year. Patients with <6 months of 
follow-up (n=146,141), no MDD diagnosis in the prior year (n=564,018), a days supply 
value ≤0 (n=1,329), or prior bipolar diagnosis (n=2,436) were sequentially excluded (Figure 
2). The final cohort included 8,837 children and 47,495 adults.
Overall, 46% of children and 45% of adults persisted on antidepressant treatment for 6 
months. Persistence was lowest among those aged 18–24 years (37%), and highest among 
children, 3–12 years of age (52%) and among our oldest adults (i.e., those 50–64 years of 
age, 52%), (Figure 3). The baseline prediction model for children (Table 1, RR>1 indicates 
increased likelihood of persistence) resulted in a c-statistic of 0.582, indicating a weak 
ability to correctly discriminate between persistent and non-persistent patients. The baseline 
prediction model for adults (Table 2) resulted in a similar c-statistic of 0.584. The sensitivity 
analysis defining persistence with a more restrictive grace period (15-day), resulted in lower 
estimates of 6-month persistence (32% in children, 34% in adults), but the models’ 
predictive abilities were similar (c-statistics: children=0.574, adults=0.588).
Days without medication
Seventy-seven percent (n=6,837) of children and 70% (n=33,212) of adults filled a second 
antidepressant prescription and therefore had a measure of days without medication between 
fills. Patients filling a second prescription were similar to the full cohort (Appendix A). In 
this subset, 59% of children and 65% of adults persisted on antidepressant treatment for 6 
months. Days without medication between the first and second antidepressant fill was 
associated with antidepressant persistence (Table 3). For example, among children with an 
antidepressant refill who had no days without medication between fills, 64% were persistent 
at 6 months compared with 46% in children who had 10–30 days without medication 
between fills. Added to the baseline prediction models, 10–30 days without medication was 
associated with a decreased likelihood of persistence in children (RR=0.72) and adults 
(RR=0.74) compared to no days (Table 3). The c-statistic moderately improved with the 
measure of days without medication, children: 0.583 (baseline model in subset with second 
prescription) to 0.617 (baseline model + days without medication) and adults: 0.603 to 
0.635.
When added to the baseline model, the measure of days without medication reclassified 36% 
of children, 57% of those had improved reclassification (Table 4). For example, in the 
baseline model, 2,984 children had a predicted probability of antidepressant persistence 52–
67% and were observed to be persistent. With the addition of days without medication, 20% 
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moved correctly into a higher stratum of predicted persistence, 16% moved incorrectly into a 
lower stratum, and 65% remained in the same stratum (Table 4). The overall NRI was 11.1, 
demonstrating that the measure improved our ability to classify patients based on those 
strata. Similarly, the measure of days without medication reclassified 37% of adults, 58% of 
those had improved reclassification (Table 4). The resulting NRI in adults was 10.7.
Prior persistence on other medications
A measure of prior persistence on other medications was available in 12% (n=5,755) of 
adults. Compared to the full adult cohort, the subset with a measure of prior persistence on 
other medications were more likely to be older and male and to have more healthcare 
utilization and co-morbidities (Appendix A). The proportion persistent on antidepressant 
treatment was higher in the subset with a measure of prior persistence (52%) than in the full 
adult cohort (45%). Among this subgroup, adults not persistent on a prior other medication 
were less likely to be persistent on antidepressant treatment than were adults who were 
persistent on a prior other medication (40% vs. 55%), RR=0.73 when added to the baseline 
model (Table 3). The addition of the measure of prior persistence on other medications to the 
baseline model improved the c-statistic (0.571 to 0.595), with the relative change being 
slightly less than the change from adding the days without medication measure. Regarding 
risk reclassification, 29% of adults were reclassified when prior persistence was added, 57% 
of those had improved reclassification, an overall NRI of 8.5 (results not shown).
In adults (n=4,195) with a measure of prior persistence on other medications and a measure 
of days without medication, 71% were persistent on antidepressant treatment. Days without 
medication resulted in a larger c-statistic improvement (0.575 to 0.616) than prior 
persistence on other medications (0.575 to 0.595) when each measure was separately added 
to the baseline model. Together the measures increased the c-statistic to 0.627. The CART 
analysis identified three patient subgroups: patients with 10–30 days without medication 
between fills (likelihood of persistence=57%), patients with 0–9 days without medication 
who were not persistent on prior other medications (64%), and patients with 0–9 days 
without medication who were persistent on prior other medications (76%).
DISCUSSION
Overall, less than half of patients with MDD who initiated antidepressant therapy were 
persistent on SSRI or SNRI treatment at 6 months, with younger children and older adults 
most likely to be persistent. Our estimates of 6-month persistence, which ranged by age 
group and grace period, are consistent with results from prior studies, 17%–56% (Esposito D 
et al., 2009; Lu C and Roughead E, 2012; Mullins CD et al., 2005; Richardson LP et al., 
2004; Sawada N et al., 2009; Tournier M et al., 2009; Wu C et al., 2012; Wu C et al., 2013; 
Yau WY et al., 2014). Our ability to predict antidepressant persistence at baseline was 
modest for both children and adults. However, days without medication between fills and 
prior persistence on other medications improved our ability to predict persistence. These 
additional factors could potentially be made available to prescribing physicians at least by 
the time of a second antidepressant prescription through prescription records to help inform 
treatment decisions and guide follow-up care.
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In the baseline prediction models we identified independent predictors unique to children 
(i.e. diagnostic code for co-morbid anxiety), predictors that had stronger associations in 
children than adults (i.e. prior outpatients visits), and factors that were predictors in both 
children and adults (i.e. code for substance use disorder). Days without antidepressant 
medication between the first and second fills was one of the strongest predictors in children 
and adults identified in this study. For adults in the final baseline model, there was not a 
difference in the likelihood of 6-month persistence for those prescribed an antidepressant by 
the provider specialty of psychiatry vs. general provider. Our finding for adults is similar to 
previous findings that a mental health professional vs. general medical provider at initial 
visit did not predict antidepressant adherence (medication possession ratio ≥75%) in adults 
with major depression (Akincigil A et al., 2007). However, studies have shown variation by 
provider in the US, for example the proportion of patients not refilling an antidepressant was 
higher among primary care providers than psychiatrists, 18% vs. 13%(Bambauer KZ et al., 
2007) and 37% vs. 32% (Lewis E et al., 2004). For children, we observed a slight decrease 
in the likelihood of persistence when the prescribing physician was a family practitioner/
general provider.
Although medical practice has the potential to be transformed by big data and software tools 
that predict the risk of an outcome for a patient, improving the quality and efficiency of 
medical care (Bates DW et al., 2014; Murdoch TB and Detsky AS, 2013), the promise of 
successfully integrating these predictive tools has yet to be consistently realized in the case 
of antidepressant adherence. For example, one study from New England (2002–2004) found 
that providing real-time fax alerts on delayed antidepressant refills to physicians was not 
successful in increasing adherence rates (Bambauer KZ et al., 2006). Whereas another study 
found that using prescription refill records resulted in modest increases in adherence to 
antidepressants among adults when non-adherent patients and providers of non-adherent 
patients received educational materials (Hoffman L et al., 2003). Our findings and earlier 
findings that the refill gap is predictive of antidepressant discontinuation (Hansen RA et al., 
2010), suggest future research is warranted to determine an effective and efficient way to 
incorporate prescription refill information to pharmacists and clinicians to improve 
antidepressant persistence.
Adherence (proportion of days with medication) to chronic medications has been associated 
with improved adherence to other treatments among adults (Curtis JR et al., 2009; Platt AB 
et al., 2010) (Simon GE et al., 2013), including adherence to antidepressants and concurrent 
adherence to an antihypertensive or lipid-lowering medication. Similarly, in our study adults 
with prior persistence on other chronic medications were more likely to persist on 
antidepressant treatment. In adults with both a measure of prior persistence and a measure of 
days without medication, days without medication offered more improvement in predicting 
persistence. A useful finding if the prescribing physician does not have information on prior 
medication use. Still, a benefit of prior persistence on other medications is that it could be 
obtained prior to beginning antidepressant treatment and possibly by simply asking a patient 
before prescribing antidepressants if they are still taking their antihypertensive or asthma 
medications, for example. Improving the prediction of persistence before antidepressant 
initiation may offer more clinical guidance in treatment type selection and early follow-up 
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care. As only 9% of adults had both measures available, our ability to compare the influence 
of these two measures was limited.
Overall, our prediction models resulted in low c-statistics (0.57–0.64), revealing a poor 
ability to discriminate persistent and non-persistent patients. C-statistics predicting 
antidepressant adherence (medication possession ratio) in claims data have been similar 
(0.56–0.61) (Akincigil A et al., 2007) or slightly higher (0.71–0.73) (Fontanella CA et al., 
2011) than our study, with the higher c-statistics from a study of Medicaid children that 
included follow-up visits and dosing. These low c-statistics reflect the multitude of factors 
that influence treatment utilization and the potential predictors available in an administrative 
claims datasource. Perhaps more important than discrimination is reclassification. Our 
overall NRIs (9–11) indicate notable improvement in reclassification when adding the 
measures days without medication and prior persistence on other medications. In the 
Framingham Heart Study, an additional measure (HDL cholesterol) added to the coronary 
heart disease risk prediction model resulted in a minimal c-statistic change but an NRI=12, 
suggesting significant improvement with the additional measure (Pencina MJ et al., 2008). 
Our reclassification results should be interpreted with caution, as there are no established 
strata (Cook NR et al., 2006; Leening MJG and Cook NR, 2013) and comparing NRIs 
across studies with different outcomes and strata may not be meaningful (Leening MJG and 
Cook NR, 2013; Leening MJG et al., 2014).
Additional limitations should be kept in mind. We cannot identify the reason patients 
discontinued antidepressants or who initiated the discontinuation (i.e. physician, patient, or 
caregiver), nor can we distinguish patients who appropriately discontinued from patients 
who may have benefited from continued antidepressant treatment. Persistence is based on 
reimbursed, dispensed prescriptions, which is an imperfect proxy for medication consumed, 
and does not include prescriptions dispensed in-hospital or samples given to the patient at 
antidepressant initiation or during treatment. Patients receiving antidepressant samples or 
receiving antidepressants during hospitalization are more likely to be misclassified as non-
persistent at 6-months as it would result in inaccurate dispensing dates or days supply 
values. The prevalence of sample use ranges by drug class and by branded vs. generic 
products (Hampp C et al., 2015; Li X et al., 2014). While there are not estimates of 
antidepressant sample use in our population, available estimates of sample use include 14% 
of patients with some prescription use (Alexander GC et al., 2008) and 13% of patients with 
a prescription for a branded statin (Li X et al., 2014).
Patients with gaps in medication use stretching past the grace period were by definition 
classified as discontinuers, even if they later continue treatment. This may include patients 
steadily taking less than the prescribed dose, possibly contributing to the association 
between antidepressant persistence and days without medication between the first and 
second fill. Patients dose titrating may have an incorrect initial days supply value, inviting 
the possibility of misclassifying the gap between prescription fills. Our findings with respect 
to prior persistence on other chronic medications may have differed if persistence on non-
chronic, non-preventative medications had been assessed. Relatedly, prior persistence on 
other medications could have been affected by MDD symptoms prior to antidepressant 
initiation. The measure of prior persistence did offer similar predictability among patients 
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with severe depression at antidepressant initiation (inpatient diagnosis or prior suicide 
attempt) and patients with less severe depression (outpatient diagnosis), results not shown. 
APA guidelines recommend a minimum treatment length of 5½ months (6–12 weeks to 
achieve symptom remission followed by 4–9 months); given our 30-day grace period, 
patients ending treatment at 5½ months would still be considered persistent at 6 months in 
this study. Ten-percent of patients had an unknown initial dose or provider; baseline models 
remained the same when excluding these patients.
Conclusion
Consistent with prior literature, we observed low 6-month antidepressant persistence in a 
population of commercially insured children and adults with MDD. Overall our ability to 
discriminate between persistent and non-persistent patients at treatment initiation was poor. 
However, days without medication coverage between fills in children and adults, and prior 
persistence on other chronic medications in adults, moderately improved our ability to 
predict antidepressant persistence. These measures could, potentially, be available to 
clinicians prior to antidepressant initiation or by the time of the second antidepressant fill 
through prescription refill records. If effectively provided to a provider, these measures 
might help identify patients with a lower likelihood of antidepressant persistence and 
thereby contribute to treatment decisions and follow-up care.
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Figure 1. 
Study schematic for predicting antidepressant persistence and identification of additional 
predictors
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Figure 2. 
Study population inclusion criteria
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Figure 3. 
Proportion of patients persistent on antidepressant treatment at 6 months by age at initiation
Error bars depict 95% confidence intervals
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Table 1
Children with major depressive disorder, predicting persistence on antidepressant treatment at six months 
(n=8,837) a
Total No. (%) Proportion persistent %
Baseline prediction model RR (95% 
CI) e
Female 5,653 (64) 46 –
Age at antidepressant initiation (years), mean ± SD 15 ± 2
 3 – 9 318 (4) 52 1.12 (1.00, 1.25)
 10 – 12 802 (9) 52 1.16 (1.07, 1.25)
 13 – 15 3,288 (37) 47 1.05 (1.00, 1.11)
 16 – 17 4,429 (50) 44 1.00 (Reference)
Index antidepressant class
 SSRI 8,469 (96) 46 –
 SNRI 368 (4) 45 –
Index dose
 Low initial dose b 2,381 (27) 48 1.07 (1.01, 1.12)
 Non-low initial dose 6,267 (71) 45 1.00 (Reference)
 Unknown dose 189 (2) 43 0.99 (0.84, 1.16)
MDD recurrent episode 3,540 (40) 45 0.94 (0.90, 0.98)
Depression Severity c
 1 outpatient diagnosis prior year 1,653 (19) 45 –
 ≥2 outpatient diagnoses prior year 5,519 (62) 48 –
 Non-primary inpatient diagnosis prior year 282 (3) 41 –
 Primary inpatient diagnosis 31–360 days prior 166 (2) 40 –
 Primary inpatient diagnosis ≤30 days prior 1,217 (14) 42 –
Suicide attempt 330 (4) 41 –
Personality disorder 133 (2) 45 –
ADHD 1,410 (16) 48 –
Anxiety 2,140 (24) 51 1.10 (1.05, 1.16)
Substance use disorder
 No substance use disorder diagnosis 8,069 (91) 47 1.00 (Reference)
 Substance use disorder diagnosis, no hospitalization 717 (8) 33 0.71 (0.64, 0.79)
 Substance use disorder related hospitalization 51 (1) 33 0.71 (0.48, 1.05)
Non-psychiatric related hospitalizations (1+) 472 (5) 43 –
Outpatient visits, mean ± SD 15 ± 13
 <5 1,406 (16) 41 1.00 (Reference)
 5 – 9 2,365 (27) 44 1.06 (0.98, 1.14)
 10 – 19 2,995 (34) 46 1.12 (1.04, 1.20)
 20 – 39 1,660 (19) 52 1.26 (1.17, 1.37)
 ≥40 411 (5) 52 1.28 (1.15, 1.43)
Generic prescription drugs, mean ± SD 4 ± 3
 Antidepressant only 1,647 (19) 44 –
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Total No. (%) Proportion persistent %
Baseline prediction model RR (95% 
CI) e
 2 – 3 3,044 (34) 46 –
 4 – 5 1,974 (22) 47 –
 6 – 9 1,628 (18) 46 –
 ≥10 544 (6) 48 –
Mid-potency opiate 1,114 (13) 45 –
Cardiac arrhythmia 240 (3) 49 –
Diabetes 105 (1) 51 –
Cluster headaches/migraines 290 (3) 47 –
Provider specialty d
 Psychiatry 3,305 (37) 48 1.00 (Reference)
 Psychology 610 (7) 47 0.97 (0.89, 1.07)
 Pediatrics 823 (9) 50 1.02 (0.95, 1.10)
 General, family practice 1,215 (14) 43 0.93 (0.87, 1.01)
 Internal medicine 265 (3) 48 1.04 (0.91, 1.18)
 Other 1,948 (22) 43 0.91 (0.86, 0.97)
 Unknown 671 (8) 45 0.97 (0.89, 1.06)
Copayment for index prescription, mean ± SD 13 ± 16
 Low copayment (<$16) 6,616 (75) 46 –
 High copayment ($16+) 2,221 (25) 45 –
SD (standard deviation), RR (risk ratio), CI (confidence interval), SSRI (selective serotonin reuptake inhibitors), SNRI (serotonin-norepinephrine 
reuptake inhibitor), ADHD (attention deficit hyperactivity disorder)
Symbol ‘ – ‘ signifies variable did not end up in the baseline prediction model
Comorbidity definitions are based on diagnostic codes recorded in the prior year; the prevalence of some conditions may be underestimated if the 
patient did not receive a diagnostic code in that year period.
a
Persistent at six-months defined as treatment for 180 days without gaps based on days supply, with 30 day grace period; all individuals were 
required to be continually enrolled for at least 180 days after antidepressant initiation
b
Low dose=3–12 years: <10mg/day (mg/d) Citalopram, Fluoxetine, and Paroxetine immediate release (IR), <12.5mg/d Paroxetine controlled 
release (CR), <25mg/d Sertraline, ≤30mg/d Duloxetine, and <37.5mg/d Venlafaxine; 13–17 years: <20mg/d Citalopram and Fluoxetine, <10mg/d 
Paroxetine IR, <12.5mg/d Paroxetine CR, <50mg/d Sertraline, <60mg/d Duloxetine, and <75mg/d Venlafaxine
c
Depression diagnoses included in severity measure: ICD-9-CM: 296.2x, 296.3x, 298.0x, 300.4x, 309.0x, 309.1x, 311.x, 293.83, 296.90, 309.28
d
Provider specialty associated with the index antidepressant prescription; ‘Unknown’ included missing, not available, and unknown
e
RR>1.00 signifies increased likelihood of persistence
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Table 2
Adults with major depressive disorder, predicting persistence on antidepressant treatment at six months 
(n=47,495) a
Total No. (%) Proportion persistent %
Baseline prediction model RR (95% 
CI) e
Female 30,458 (64) 46 –
Age at antidepressant initiation (years), mean ± SD 40 ± 13
 18 – 24 8,187 (17) 37 1.00 (Reference)
 25 – 34 8,935 (19) 42 1.13 (1.09, 1.18)
 35 – 49 17,432 (37) 47 1.26 (1.22, 1.30)
 50 – 64 12,941 (27) 52 1.39 (1.34, 1.44)
Index antidepressant class
 SSRI 40,265 (85) 45 1.00 (Reference)
 SNRI 7,230 (15) 49 1.07 (1.04, 1.10)
Index dose
 Low initial dose b 6,710 (14) 43 0.93 (0.90, 0.96)
 Non-low initial dose 39,578 (83) 46 1.00 (Reference)
 Unknown dose 1,207 (3) 49 1.06 (1.00, 1.12)
MDD recurrent episode 25,765 (54) 46 –
Depression severity c
 1 outpatient diagnosis prior year 13,740 (29) 46 1.00 (Reference)
 ≥2 outpatient diagnoses prior year 29,429 (62) 46 1.00 (0.98, 1.02)
 Non-primary inpatient diagnosis prior year 1,608 (3) 39 0.94 (0.88, 1.00)
 Primary inpatient diagnosis 31–360 days prior 397 (1) 39 0.90 (0.80, 1.02)
 Primary inpatient diagnosis ≤30 days prior 2,321 (5) 37 0.91 (0.86, 0.97)
Suicide attempt 511 (1) 37 –
Personality disorder 639 (1) 41 –
ADHD 1,497 (3) 42 –
Schizophrenia 272 (1) 43 –
Anxiety 13,105 (28) 46 –
Substance use disorder
 No substance use disorder diagnosis 41,455 (87) 47 1.00 (Reference)
 Substance use disorder diagnosis, no hospitalization 5,557 (12) 37 0.84 (0.81, 0.87)
 Substance use disorder related hospitalization 483 (1) 31 0.70 (0.61, 0.81)
Non-psychiatric related hospitalization (1+) 5,320 (11) 42 –
Outpatient visits, mean ± SD 19 ± 18
 <5 7,103 (15) 44 1.00 (Reference)
 5 – 9 10,498 (22) 45 1.02 (0.99, 1.06)
 10 – 19 14,058 (30) 45 1.03 (1.00, 1.07)
 20 – 39 10,887 (23) 46 1.07 (1.03, 1.11)
 ≥40 4,949 (10) 47 1.08 (1.04, 1.13)
Generic prescription drugs, mean ± SD 6 ± 5
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Total No. (%) Proportion persistent %
Baseline prediction model RR (95% 
CI) e
 Antidepressant only 4,835 (10) 47 1.00 (Reference)
 2 – 3 11,578 (24) 46 0.98 (0.95, 1.02)
 4 – 5 9,472 (20) 47 1.00 (0.97, 1.04)
 6 – 9 12,227 (26) 45 0.97 (0.94, 1.01)
 ≥10 9,383 (20) 43 0.93 (0.89, 0.97)
High-potency prescription opiate usage 905 (2) 39 0.92 (0.84, 0.99)
Mid-potency prescription opiate usage 14,088 (30) 41 0.88 (0.86, 0.91)
Cancer, malignant neoplasm 1,769 (4) 50 –
Arthritis 422 (1) 48 –
Osteoarthritis 2,914 (6) 48 –
Postural hypotension 129 (0) 51 –
Congestive heart failure 561 (1) 44 –
Cardiac arrhythmia 2,064 (4) 45 –
Urinary incontinence 445 (1) 44 –
Diabetes 3,595 (8) 47 –
Cerebrovascular disease 1,071 (2) 45 –
Gait or balance disorder 575 (1) 48 –
Cluster headaches/migraines 2,320 (5) 43 –
Seizures 473 (1) 45 –
Osteoporosis 771 (2) 48 –
Provider specialty d
 Psychiatry 13,836 (29) 47 1.00 (Reference)
 Psychology 2,842 (6) 45 0.95 (0.90, 0.99)
 General, family practice; pediatrics 12,163 (26) 47 1.02 (0.99, 1.05)
 Internal medicine 4,501 (9) 47 0.99 (0.95, 1.02)
 Other 10,666 (22) 42 0.92 (0.89, 0.94)
 Unknown 3,487 (7) 43 0.94 (0.91, 0.98)
Copayment for index prescription, mean ± SD 17 ± 22
 Low copayment (<$24) 35,505 (75) 46 –
 High copayment ($24+) 11,990 (25) 45 –
SD (standard deviation), RR (risk ratio), CI (confidence interval), SSRI (selective serotonin reuptake inhibitors), SNRI (serotonin-norepinephrine 
reuptake inhibitor), ADHD (attention deficit hyperactivity disorder)
Symbol ‘ – ‘ signifies variable did not end up in the baseline prediction model
Comorbidity definitions are based on diagnostic codes recorded in the prior year; the prevalence of some conditions may be underestimated if the 
patient did not receive a diagnostic code in that year period.
a
Persistent at six-months defined as treatment for 180 days without gaps based on days supply, with 30 day grace period; all individuals were 
required to be continually enrolled for at least 180 days after antidepressant initiation
b
Low dose=18–64 years: <20mg/day (mg/d) Citalopram, Fluoxetine, and Paroxetine immediate release, <25mg/d Paroxetine controlled release, 
<50mg/d Sertraline, <60mg/d Duloxetine, and <75mg/d Venlafaxine
c
Depression diagnoses included in severity measure: ICD-9-CM: 296.2x, 296.3x, 298.0x, 300.4x, 309.0x, 309.1x, 311.x, 293.83, 296.90, 309.28
d
Provider specialty associated with the index antidepressant prescription; ‘Unknown’ included missing, not available, and unknown
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e
RR>1.00 signifies increased likelihood of persistence
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Table 3
Association of days without medication between fills and prior persistence on other chronic medications with 
antidepressant persistence
Total No. Proportion persistent to 
antidepressant %
Baseline prediction model a + 
additional measure
RR (95% CI)
CHILDREN
 Days without medication between fills (n=6,828) b
  0 days 3,707 64 1.00 (Reference)
  1 – 9 days 2,001 58 0.91 (0.87, 0.95)
  10–30 days 1,120 46 0.72 (0.67, 0.77)
ADULTS
 Days without medication between fills (n=33,212) b
  0 days 17,375 70 1.00 (Reference)
  1 – 9 days 10,101 64 0.92 (0.90, 0.93)
  10–30 days 5,736 52 0.74 (0.72, 0.76)
 Prior persistence on other chronic medication (n=5,755) c
  Persistent on other medication 4,583 55 1.00 (Reference)
  Not persistent on other medication 1,172 40 0.73 (0.68, 0.79)
RR (risk ratio), CI (confidence interval)
a
Baseline prediction model for children: age, initial low dose, recurrent major depressive disorder, anxiety diagnosis, substance use, outpatient 
visits, provider specialty; adults: age, antidepressant class, initial low dose, depression severity, substance use, outpatient visits, prescription count, 
high and mid-potency opiate usage, hypotension, provider specialty
b
Measure of the number of days without medication between the first and second antidepressant fill, based on dispensing dates and days supply, 
among children and adults with a second antidepressant fill
c
Prior persistence on other medications measured whether an individual remained on an anti-hyperlipidemic, antihypertensive, bone-density 
regulator, or chronic asthma medication for at least 6 months in the year prior to antidepressant initiation
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Table 4
Reclassification of predicted probabilities of antidepressant persistence with the measure of days without 
medication added to the baseline model, children (n=6,828) and adults (n=33,212)
Baseline model + days without medication a
Baseline model, Predicted probabilities
Frequency (row %)
CHILDREN b <52.0% 52.0 to 67.0% >67.0% Total, No.
 Persistent on antidepressant
  <52.0% 258 (67%) 129 (33%) 0 387
  52.0 to 67.0% 469 (16%) 1,932 (65%) 583 (20%) 2,984
  >67.0% 15 (2%) 172 (25%) 504 (73%) 691
 Not persistent on antidepressant
  <52.0% 320 (74%) 113 (26%) 0 433
  52.0 to 67.0% 570 (28%) 1,221 (59%) 281 (14%) 2,072
  >67.0% 10 (4%) 82 (31%) 169 (65%) 261
ADULTS b <57.2% 57.2 to 72.2% >72.2% Total, No.
 Persistent on antidepressant
  <57.2% 2,142 (61%) 1,373 (39%) 0 3,515
  57.2 to 72.2% 1,924 (15%) 7,842 (61%) 3,152 (24%) 12,918
  >72.2% 164 (3%) 1,134 (22%) 3,759 (74%) 5,057
 Not persistent on antidepressant
  <57.2% 2,294 (71%) 930 (29%) 0 3,224
  57.2 to 72.2% 1,871 (27%) 3,907 (57%) 1,026 (15%) 6,804
  >72.2% 109 (6%) 538 (32%) 1,047 (62%) 1,694
a
Measure of the number of days without medication between the first and second antidepressant fill, based on dispensing dates and days supply, 
among children and adults with a second antidepressant fill
bOverall NRI=11.1 (children) and 10.7 (adults); NRI calculation = [(number of persistent patients classified up − number of persistent patients 
classified down)/total number of persistent patients] + [(number of non-persistent patients classified down − number of non-persistent patients 
classified up)/total number of non-persistent patients]
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